Table 36Propiverine vs oxybutynin - Clinical study characteristics and clinical summary of findings

No. of studiesDesignTreatment (n)Control (n)ResultsLimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
Outcome: Continence
1 [A]ObservationalPropiverine
N=127
Oxybutynin
N=128
% continent Before vs after Propiverine 7.7 vs 31.6 Oxybutynin 20.8 vs 50.4S (i)NNN (ii)NVery low
Outcome: Maximum cystometric capacity
1 [A]ObservationalPropiverine
N=127
Oxybutynin
N=128
Before vs after mL Propiverine 145.9 vs 242.3 Oxbutynin 221.8 vs 310.0S (i)NNN (ii)NVery low
Outcome: Adverse events
1 [A]ObservationalPropiverine
N=127
Oxybutynin
N=128
Propiverine 11/127 Oxybutynin 22/128 RR 0.50 (95%CI 0.26 to 1.00)NNNY (iii)NVery low

S serious N none

RR relative risk CI confident interval

i

Differences at baseline

ii

Imprecision not assessed, data at high risk of bias

iii

The 95%CI crosses the minimally important difference (MID) for either benefit or harm

[A]

Madersbacher et al. (2009)56

Differences at baseline

Imprecision not assessed, data at high risk of bias

The 95%CI crosses the minimally important difference (MID) for either benefit or harm

Madersbacher et al. (2009)56

From: 8, Treatment to improve bladder storage

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.